

Particle Uptake Driven Phagocytosis in Macrophages and Neutrophils Enhances Bacterial Clearance

Preeti Sharma¹, Anjali Vijaykumar¹, Jayashree Vijaya Raghavan¹, Supriya Rajendra Rananaware², Alakesh Alakesh¹, Janhavi Bodele¹, Junaid Ur Rehman¹, Shivani Shukla¹, Virta Wagde¹, Savitha Nadig³, Sveta Chakrabarti⁴, Sandhya S. Visweswariah⁴, Dipankar Nandi², Balasubramanian Gopal³, Siddharth Jhunjhunwala^{1*}

1 – Centre for BioSystems Science and Engineering,

2 – Department of Biochemistry,

3 – Molecular Biophysics Unit

4 – Department of Molecular Reproduction, Development and Genetics

Indian Institute of Science, Bengaluru, India – 560012

*Address correspondence to siddharth@iisc.ac.in

Abstract:

Humans are exposed to numerous synthetic foreign particulates in the form of environmental pollutants and diagnostic or therapeutic agents. Specialized immune cells (phagocytes) clear these particulates by phagocytosing and attempting to degrade them. The process of recognition and internalization of the particulates may trigger changes in the function of phagocytes. Some of these changes, especially the ability of a particle-loaded phagocyte to take up and neutralize pathogens, remains poorly studied. Herein, we demonstrate that the uptake of non-stimulatory cargo-free particles enhances the phagocytic ability of monocytes, macrophages and neutrophils. The enhancement in phagocytic ability was independent of particle properties, such as size or the base material constituting the particle. Additionally, we show that the increased phagocytosis was not a result of cellular activation or cellular heterogeneity but was driven by changes in cell membrane fluidity and cellular compliance. A consequence of the enhanced phagocytic activity was that particulate-laden immune cells neutralize *E. coli* faster in culture. Moreover, when administered in mice as a prophylactic, particulates enable faster clearance of *E. coli* and *S. epidermidis*. Together, we demonstrate that the process of uptake induces cellular changes that favor additional phagocytic events. This study provides insights into using non-stimulatory cargo-free particles to engineer immune cell functions for applications involving faster clearance of phagocytosable particulates.

1 **Introduction**

2 Specialized immune cells utilize the process of phagocytosis for both tissue homeostasis and
3 host defense.¹⁻³ As part of host defense, these phagocytic immune cells take up foreign
4 particulates such as microbial pathogens, diagnostic or therapeutic agents,⁴ and micrometer-
5 sized environmental pollutants,⁵ and attempt to degrade them within intracellular compartments.
6 The process of interaction with and uptake of foreign substances may change the phenotype
7 and function of the phagocytic immune cells, a phenomenon widely investigated in the context
8 of microorganisms.⁶ In contrast, the effects of uptake of synthetic particulates on immune cell
9 functions are relatively less explored.

10 Based on the physicochemical properties of a synthetic particle, reports have suggested that
11 phagocytic immune cells may be activated towards an inflammatory⁷⁻⁹ or anti-inflammatory
12 phenotype.^{8,10-13} Additionally, uptake of particles may alter cytokine secretion, chemotaxis
13 behavior, oxidative burst, and nitric oxide generation in these cells.¹³⁻²⁰ However, it remains
14 unclear if the uptake of particles would affect the ability of a phagocytic immune cell to
15 subsequently phagocytose and neutralize a pathogen.

16 In this study, we determine how the uptake of particles changes an immune cell's phagocytic
17 and bactericidal abilities. Using various phagocytic cell types and particles, we demonstrate that
18 uptake of a non-stimulatory cargo-free particle enhances the phagocytic ability of immune cells.
19 We show that this increased phagocytosis is not a result of cellular activation or cellular
20 heterogeneity; instead, the uptake of particles drives subsequent phagocytic events. Finally, we
21 demonstrate that a consequence of the enhanced uptake ability is faster clearance of bacteria
22 both *in vitro* and *in vivo*.

23

24 **Results:**

25

26 **Sequential Phagocytosis**


27 Phagocytic immune cells have the ability to engulf multiple particulates. Given the ever-
28 increasing exposure of humans to foreign particulates, phagocytic cells might encounter
29 particulates followed by pathogens in a sequential manner. The question of interest to us was
30 whether the phagocytic ability of these cells is altered after an uptake event. To address this
31 question, we sequentially added particles labeled with two different fluorophores, to cells in
32 culture (Figure 1A). We quantified the fraction of cells that had taken up both the particles
33 (sequential uptake) and compared them to the fraction of cells that had only taken up the
34 particle added second in the sequence (bystander uptake). We observed that sequential uptake
35 was significantly higher than bystander uptake for all combinations of polystyrene (PS) particle
36 (carboxyl-modified surfaces) sizes tested (Figure 1B and supplementary figure 1A). Besides, the
37 number of particles phagocytosed by cells in the second round, quantified as median
38 fluorescence intensity (MFI), was also higher for cells that had taken up particles in the first
39 round (Supplementary figure 1B and 1C). Notably, the number of particles taken up by a cell in
40 the second round significantly increased with the number of particles it phagocytosed in the first
41 round, suggesting dose-dependent priming of phagocyte for the second round of uptake
42 (Supplementary figure 2A and 2B). Furthermore, the phenomenon of enhanced sequential
43 phagocytosis was independent of the time of incubation with particles in the first round
44 (Supplementary 2C), for the timeframes we tested.

45

46 Physicochemical properties of the bulk material and the surface characteristics of particulates
47 are known to dictate the particle-immune cell interaction.²¹ To determine if these properties
48 affected the sequential phagocytosis capacity, we used particles composed of materials
49 approved for clinical use, such as PLGA, PCL and Silica. Uptake of particles made of these
50 materials also resulted in enhanced sequential phagocytosis (Figure 1C). Additionally, cells that
51 take up PS particles whose surfaces do not have a carboxyl group or those that have been
52 modified with polyethylene glycol (PEG) also showed the capacity for increased phagocytosis
53 (Supplementary Figure 3).


54

55 The phenomenon of enhanced sequential phagocytosis was observed in another cell line (dHL-
56 60), and among primary monocytes and neutrophils isolated from peripheral venous blood of
57 humans (Figure 2A). Interestingly, this phenomenon was not limited to mammalian systems, as



58 hemocytes isolated from *Drosophila melanogaster* larvae also showed increased sequential
 59 phagocytosis (Figure 2B), suggesting that this phenomenon was conserved across phylae. To

60 determine if sequential uptake was observed *in vivo*, fluorescent particles were sequentially
61 administered via the intraperitoneal route in mice, and increased sequential phagocytosis was
62 observed in the peritoneal macrophages (Figure 2C).
63



64
65 We hypothesized that the increase in the ability of cells to phagocytose particles following an
66 initial uptake event could be due to: (i) cellular activation through TLR stimulation during the first
67 round of phagocytosis; or (ii) pre-existing cellular heterogeneity – that is, some cells are
68 inherently more phagocytic; or (iii) the first uptake event drives cellular changes that enhance a
69 cell's ability to phagocytose substances.

70

71 **Cellular activation Does Not Drive Enhanced Sequential Phagocytosis**

72 Phagocytosis of silica and iron oxide particles have been reported to activate immune cells
73 towards pro-inflammatory phenotype characterized by secretion of inflammatory cytokines and
74 generation of reactive oxygen and nitrogen species.^{18,20} Activated immune cells are thought to
75 have an increased phagocytic ability. Further, the presence of contaminating sources of
76 lipopolysaccharide (LPS) on particles could result in increased uptake. We investigated whether
77 the enhanced phagocytic ability observed in our experiments is due to cellular activation
78 following Toll-like receptor (TLR)-4 stimulation. We conducted sequential phagocytosis
79 experiments with RAW cells that were activated with LPS. TLR stimulation with LPS is known
80 to increase the number of cells that will undergo phagocytosis²², which was confirmed in the
81 present study as well (Supplementary Figure 4A). We observed enhanced sequential
82 phagocytosis even after uniform pre-activation of cells with LPS (Figure 3A). Next, we blocked
83 the TLR-4 pathway using a chemical inhibitor (TAK-242²³) prior to the sequential addition of
84 particles. The inhibitor was able to prevent an LPS-mediated increase in overall phagocytosis
85 (Supplementary Figure 4B and 4C). However, even in the presence of this inhibitor, cells
86 showed increased sequential uptake (Figure 3B).

87

88 Activated immune cells are known to produce reactive oxygen species (ROS), nitric oxide (NO)
89 and upregulate the expression of inflammatory cytokines.²⁴ We investigated if uptake of PS
90 particles stimulates cells towards an activated phenotype. We observed that while LPS or LPS +
91 IFN γ stimulated cells in culture produced increased levels of intracellular ROS (Figure 3C), NO
92 (Figure 3D) and the inflammatory cytokines IL-1 β , IL-6 and TNF- α (Figure 3E), cells that had
93 phagocytosed PS particles did not show any changes in the levels of these molecules
94 compared to controls (naïve cells in culture), showcasing the non-stimulatory nature of these
95 particulates. Further, the anti-inflammatory or M2-type cytokine, IL-10, remained undetectable in
96 all these culture conditions. Collectively, these data suggest that enhanced sequential
97 phagocytosis is not a result of traditional cellular activation caused by TLR stimulation.

98

99 **Cellular Heterogeneity is Not Necessary for Enhanced Sequential Phagocytosis**

100 Recent studies^{25,26} have suggested that differing phagocytic capacities within a given
101 population of immune cells might result in a subset of these cells taking up more bacteria. We
102 used a mouse macrophage cell line to determine if heterogeneity explains the observed
103 increases in sequential uptake. For the first set of experiments, we incubated cells with PS





Figure 3: Sequential uptake is not due to TLR based cellular activation. **A** – Uptake of 500 nm-carboxylated polystyrene (PS) particles by RAW macrophages (1:50 cell to particle ratio) following pre-activation of all cells with LPS (1 μ g/ml for 18 hours). **B** – Sequential uptake of 500 nm-carboxylated PS particles by RAW macrophages following the treatment of cells with TAK-242 (2 μ M for 6 hours) to block TLR-4 mediated cellular activation. **C** – Intracellular reactive oxygen species (ROS) quantified using flow cytometry following incubation of RAW macrophages with 500 nm-carboxylated PS particles (1:50 cell to particle ratio) for 2 or 18 hours, or with LPS for 18 hours. Data are normalized to ROS production in cells that were left untreated for the same times. **D** – Intracellular nitric oxide (NO) production determined after incubating cells with 500 nm-carboxylated PS particles (1:10 cell to particle ratio; lower particle ratio was used due to length of incubation) or LPS and IFN- γ for 36 hours. Extracellular NO production determined after incubating cells with 500 nm-carboxylated PS particles (1:100 cell to particle ratio) or LPS and IFN- γ for 36 hours. **E** – Relative mRNA expression of pro-inflammatory cytokine genes (IL-1 β , IL-6 and TNF- α) measured using RT-qPCR. Data are based on $n \geq 3$ independent experiments (each performed in duplicate). * = $p < 0.05$ ** = $p < 0.01$ and *** = $p < 0.001$ determined using paired Student's t -test or one-way ANOVA.

105 particle, suggesting a close to homogenous population in terms of a phagocytic event. We
106 observe that these cells showed a higher phagocytic ability (percentage of cells with particles)
107 when compared to naïve cells that had not been exposed to particles (Supplementary Figure 5).



108

109 Separately, we also incubated cells with a lower number of particles that lead to approximately
110 half the cells in a culture-dish taking up particles, resulting in a heterogeneous population in
111 terms of a phagocytic event. These cells were then sorted to separate cells containing particles
112 (particle-positive) from cells that did not take up particles (particle-negative). The sorted cells

113 were then cultured with particles labeled with two different fluorophores in a sequential manner
114 (Figure 4A). The particle-negative cells, which could possibly be considered as a homogenous
115 population of cells with lower phagocytic capacity, also showed enhanced sequential
116 phagocytosis ability (Figure 4B). Additionally, the 'particle-positive' cells were not only capable
117 of further phagocytosis but demonstrated increased sequential phagocytosis ability (Figure 4C).
118 These data suggest that increased phagocytic ability is not likely due to cellular heterogeneity
119 alone, at least in this cell line.

120

121 Phagocytosis Induces Changes in Membrane Fluidity and Cellular Stiffness

122 Having observed that neither cellular activation nor cellular heterogeneity could explain the
123 enhanced sequential phagocytosis phenomena, we explored if phagocytosis induces changes
124 in cells that might result in increased uptake. Both the cell membrane and the cytoskeleton are
125 actively involved in phagocytosis, and hence we assessed changes to these structures following
126 uptake of PS particles. Using a fluorescent probe that detects perturbations in membrane phase




Figure 5: Phagocytosis induced changes in macrophage membrane fluidity and cellular stiffness. **A** – Measurement of membrane fluidity using the generalized polarization (GP) value for the membrane dye Laurdan in RAW macrophages that were incubated with 500 nm-carboxylated polystyrene (PS) particles at two different cell-to-particle ratios and compared to the negative control of naïve cells (cells) as well as the positive control of cells treated with methyl-beta-cyclodextrin (MβCD). $n = 6$ independent experiments. * indicates $p < 0.05$, ** indicates $p < 0.01$ and *** indicates $p < 0.001$ calculated using one-way ANOVA followed by Bonferroni post-hoc test for comparison of multiple groups. **B** – Measurement of apparent modulus of a cell using atomic force microscopy. Young's modulus of naïve cells (Cells) and cells that have been treated with 500 nm-carboxylated PS particles (With Particles) is plotted, with each dot representing a single cell. Data sets are representative of at least 60 cells measured across 3 independent experiments. * indicates $p < 0.05$ calculated using unpaired t -test with Welch's correction.

127 properties, we determined that the fluidity (measured based on generalized polarization value of
128 the dye) of the membranes of cells that have phagocytosed PS particles was significantly higher
129 as compared to naïve cells (Figure 5A). Methyl-beta-cyclodextrin (M β CD), a cholesterol-
130 depleting agent, was used as a positive control in these experiments and shows the highest
131 increases in membrane fluidity. Increased membrane fluidity has been associated with higher
132 phagocytic ability²⁷, and the above observation suggests that one possible explanation for the
133 enhanced sequential phagocytosis could be changes in fluidity of cell membranes.

134

135 Additionally, a cell must change its shape to internalize phagocytic targets. Hence, we
136 measured the ability of a cell to deform by estimating the cellular stiffness using force-distance
137 spectroscopy in an atomic force microscope. The Young's modulus of cells that had
138 phagocytosed 500 nm-carboxylated PS particles was significantly lower than naïve cells (Figure
139 5B and Supplementary Figure 6), indicating an enhanced ability to deform, which might partly
140 explain the increase in phagocytic capacity.

141

142 **Increased *in vitro* clearance of *E. coli***


143 The primary function of phagocytic immune cells is to recognize, phagocytose and degrade
144 pathogenic microorganisms.^{3,28} Phagocytic cells that have internalized particles might encounter
145 bacteria; hence, we examined the effect of particle uptake on the internalization and killing of
146 bacteria by phagocytic immune cells. We used *E. coli* as a model system for these studies. The
147 bacteria were added to macrophage cell-line cultures (MOI 3.3 - 44) that had either been
148 exposed to PS particles (at a dose that resulted in >90% cells having particles) or naïve cells. In
149 concurrence with our enhanced sequential uptake data, at 2 hours post *in vitro* infection, we
150 observed increased internalization of *E. coli* by RAW macrophages that had taken up particles
151 compared to naïve cells (Figure 6A). Higher bacterial numbers (measured as colony-forming
152 units (CFUs)) were observed in cells with particles at 6 hours too; however, by 18 hours, the
153 bacterial numbers in cells with particles were similar to that of naïve cells. Upon calculation of
154 the clearance of bacteria, which is the number internalized initially to the number that remained
155 at the end of measurements, we observe that cells with particles had cleared a greater
156 percentage of bacteria (Figure 6B).

157

158 **Unaltered invasion and replication of *S. Typhimurium* inside macrophages with particles**

159 Bacteria such as *Salmonella* are known to invade, survive and replicate inside phagocytic
160 immune cells actively. So, we evaluated if the phenomenon of enhanced sequential

161 phagocytosis would alter the interaction of such bacteria with phagocytes. We added *S.*
162 Typhimurium, an intracellular pathogen, to RAW macrophage cultures (*in vitro*) (MOI 5 - 50) and
163 observed that the numbers of intracellular bacteria were not different in cells with PS particles
164 when compared to cells without particles (Supplementary Figure 7). This observation is not
165 surprising as these specific bacteria actively invade macrophages, in addition to being taken up
166 by phagocytosis. Further, the numbers of these bacteria continued to remain equally high in
167 both cells with particles and naïve cells, which might also be expected as we show that the
168 uptake of the non-stimulatory cargo-free PS particle only affects the cell's phagocytic ability and



169 not the cell's activation and killing mechanisms such as ROS, NO or cytokine production.


170

171 **Phagocytosis of non-stimulatory particles increases the rate of *E. coli* clearance *in vivo***

172 Next, we investigated the effect of particle phagocytosis by immune cells on the bacterial killing
173 kinetics using an animal model of bacterial infection. For this, particles were injected in C57BL/6
174 mice via intraperitoneal route 2 hours prior to *E. coli* infection at the same site. Bacterial load
175 was measured in the peritoneal exudate, within peritoneal exudate cells, and in distant sites
176 such as the spleen, kidney and liver. Mice injected with particles showed significantly lower
177 bacterial load in peritoneal exudate cells (intracellular) (Figure 7A) and peritoneal exudate
178 (Figure 7B) at 6 hours after bacterial injection compared to mice injected with saline followed by
179 bacteria (controls). Additionally, the bacterial burden was found to be significantly reduced in the

180 spleen (Figure 7C) and lowered but not statistically significant in the kidney (Figure 7D) of mice
181 injected with particles. In all the mice, we did not detect any bacteria infiltrating the liver.

182
183 The total number of immune cells in the peritoneal exudate 2 hours after particle injection was
184 not significantly different from the saline-injected mice, indicating that the faster clearance of
185 bacteria was not due to increased immune cell infiltration (Supplementary Figure 8). The faster
186 killing of bacteria could also occur if immune cells are activated in mice prior to administration of
187 bacteria. Thus, to determine the activation status of immune cells after they have taken up
188 particles, we compared the expression of various activation markers on isolated mouse
189 peritoneal macrophages, which had phagocytosed particles, to that of untreated naïve
190 peritoneal macrophages from the same animals. There was no significant difference in the
191 expression of CD11b, CD38, CD54, CD62L and CD86 between naïve cells and cells with




192 particles (Supplementary Figure 9). Together, these data suggest prophylactic particle
193 administration, which results in enhancing the phagocytic capacity of phagocytes, leads to faster
194 clearance of *E. coli*.

195

196 **Phagocytosis of non-stimulatory particles increases the rate of *S. epidermidis* clearance**
197 ***in vivo***

198 As *E. coli* is killed by most phagocytic immune cells, we next chose to use a pathogen that is
199 primarily killed by a specific phagocytic immune cell. *S. epidermidis*, a nosocomial pathogen
200 associated with heavy clinical burdens, is primarily neutralized by neutrophils.²⁹ To investigate if
201 enhancing the phagocytic ability of immune cells can effectively contain the spread of *S.*
202 *epidermidis*, we injected particles and bacteria sequentially. Bystander and sequential uptake
203 were determined in neutrophils, macrophages, and monocytes from the peritoneal cavity
204 (Supplementary Figure 10). In concurrence with *in vitro* data on enhanced sequential
205 phagocytosis after particle uptake, our *in vivo* data shows that cells containing particles
206 phagocytose a higher number of bacteria than cells without particles in the same mouse or
207 compared to cells in mice that were not injected with particles (particle-naïve mouse) (Figure
208 8A). Particle-injected mice showed a trend of lower bacterial burden in the peritoneal space
209 (Figure 8B and 8C). Importantly, in particle-injected mice, we observed that the dissemination of
210 bacteria to distant organs was significantly lowered, with a complete absence of bacteria in the
211 kidney (Figure 8D) and close to zero bacteria after 24 hours in the spleen (Figure 8E), as
212 compared to particle-naïve mice. These data also indicate that prophylactic administration of
213 non-stimulatory particles results in faster clearance and prevention of bacterial spread.

214



216 Discussion

217

218 *In vivo* administration of particles results in a large proportion of them being sequestered by
219 phagocytic immune cells. A recent meta-analysis of nanoparticle-based cancer therapeutics by
220 Warren Chan and colleagues showed that only 0.7% of the administered particles reach the
221 target tumor site in mouse models³⁰, implying that most of the particles are sequestered by
222 phagocytic cells. Even if the particles are degradable, once phagocytosed, they may be
223 associated with the immune cells for days to weeks.^{31,32} Hence, apart from understanding *in*
224 *cellulo* and *in vivo* fate of the particulates, which is well studied³³⁻³⁶, it is crucial to understand
225 the impact of particulate phagocytosis on the immune cell's functionality.

226

227 A cell's capacity to phagocytose particulates depends on factors such as its polarization state,
228 expression levels of various proteins associated with phagocytosis, and environmental cues
229 such as cytokines present in the extracellular milieu.^{37,38} A change in any of these factors may
230 be used to modulate its uptake capacity. For example, stimulating macrophages with LPS or
231 IFN γ , which activate NF- κ B, results in heightened phagocytic activity.²² However, these
232 methods to modulate phagocytic activity are generally accompanied by other cellular changes,
233 such as the production of inflammatory cytokines and reactive oxygen and nitrogen species by
234 M1 phenotypic cells, which is likely to cause damage to surrounding cells and tissues.³⁹
235 Contrasting these conventional methods of cellular activation, we show that monocytes,
236 macrophages and neutrophils may be driven towards a phenotype that shows enhanced
237 phagocytic activity without eliciting an inflammatory immune response. This observation is
238 independent of particle size, is conserved across various phagocytic cell types and is seen in
239 different organisms, suggestive of its universality.

240

241 Phenotypic and functional heterogeneity among immune cells is now well recognized.⁴⁰
242 Hellebrekers et al. showed that neutrophils have increased phagocytic capacity following *S.*
243 *aureus* uptake²⁵, while Sachdeva et al.²⁶ showed that endocytosis increases phagocytic
244 capacity in macrophage cell lines. Both these studies attributed the increased phagocytosis to
245 heterogeneity among cells, with a unique highly endocytic/phagocytic cell population
246 responsible for the increased uptake. While heterogeneity in phagocytic capacity exists, our cell-
247 sorting data imply that an increase in phagocytic capacity may also be induced. Cells that did
248 not initially take up particles (bystander cells) show enhanced sequential phagocytosis when
249 provided with new phagocytic targets in our cell-sorting experiment, suggesting that uptake is

250 able to drive additional phagocytosis. While heterogeneous cells may exist even after cell
251 sorting, we are unlikely to expect a large proportion of them to be highly phagocytic cells.
252 Additional proof for uptake-driven increases in phagocytosis comes from the changes we
253 observe to the fluidity of cell membranes and the Young's modulus of a cell.

254
255 Modulation of phagocytic immune cell function may prove beneficial for a wide range of
256 diseases. Generally, such modulation is achieved through therapeutic molecules that may be
257 delivered with the help of particles. However, a few recent studies have shown that non-
258 stimulatory cargo-free particles may also reprogram immune cell behavior and have
259 demonstrated their use in the treatment of conditions such as inflammatory bowel disease,
260 acute lung injury, sepsis and West Nile infection⁴¹⁻⁴⁴. However, the effects of particles observed
261 in these studies is thought to be due to the diversion of immune cells away from the
262 inflammatory site to secondary lymphoid organs. Highlighting the modulation at the cellular
263 level, our results suggest that phagocytosable cargo-free non-stimulatory particulates may be
264 used in conditions that are marked by impaired phagocytosis. We demonstrate that one such
265 application is the increased rate of clearance and reduction in the systemic dissemination of *E.*
266 *coli* and *S. epidermidis*. Other possible applications could include assisting with clearance of
267 pathogens from lungs in patients with impaired phagocytic activity^{45,46}, faster clearance of
268 apoptotic cells in inflammatory diseases^{47,48} and in improving wound-healing.

269
270 Finally, it is important to note that the non-stimulatory cargo-free particulates change an immune
271 cell's phagocytic ability but not killing capacity. So, the strategy of using particulates for faster
272 bacterial clearance is unlikely to work for pathogens that have active evasion or survival
273 mechanism. Also, the increase in phagocytic ability is brought about after particle uptake, and
274 hence the particle administration may only be used for prophylactic treatments and not as a
275 therapeutic.

276
277 In conclusion, we show that uptake of particles drives additional phagocytosis in immune cells.
278 Hence, we may utilize non-stimulatory cargo-free particles to increase the phagocytic ability of
279 immune cells that could have applications in improving bacterial clearance. The work presented
280 here also indicates that particles may have unintended effects on the functionality of immune
281 cells, which should be addressed when evaluating the compatibility of newly designed nano-
282 and micro-particulates for clinical use.

283

284 **Materials and methods**

285

286 ***In vitro* sequential phagocytosis**

287 RAW 264.7 cells were cultured in DMEM (Lonza, India) supplemented with 10% FBS and 1%
288 antibiotic-antimycotic solution (Thermo-fisher Scientific, USA). HL-60 cells were cultured in
289 IMDM (Merck, USA) supplemented with 20% FBS and 1% antibiotic-antimycotic solution. These
290 cells were induced towards granulocytes (d-HL60) with 1.25% DMSO (Merck), for 3 days. Both
291 cell lines were seeded at a density of 2×10^5 cells per well (of a 24-well plate) and incubated for
292 2 hours at 37°C under 5% CO₂. For phagocytosis studies, carboxylated polystyrene (PS)
293 particles of various sizes (200 nm, 500 nm, 1000 nm and 2900 nm) labeled with different
294 fluorophores (Dragon-green or Flash-red) were used (Bangs Laboratories, Indiana, USA).
295 Fluorescent bovine serum albumin (BSA) loaded ~2500 nm-sized Poly(lactic-co-glycolic acid)
296 (PLGA), and ~2000 nm-sized polycaprolactone (PCL) particles were synthesized using the
297 double emulsion solvent evaporation method.⁴⁹ Silica particles with a diameter of 3000 nm
298 (Bangs Laboratories) were tagged for fluorescence by adsorbing fluorescently labelled BSA on
299 the particle surface. For the first round of phagocytosis, particles labeled with fluorophore 1
300 were added to the cells at different ratios (exact ratios specified in the figure legends). After co-
301 incubation of cells and particles for various time intervals, media containing free-floating
302 particles was removed, cells were washed with 1 X PBS to ensure minimal to no residual
303 particles, and fresh media was added. Cells were then incubated with particles labelled with
304 fluorophore 2 for a specified time interval. Finally, media was removed, wells washed with 1 X
305 PBS, cells scraped, stained with 2 µg/ml propidium iodide (PI) solution, and analyzed on a flow
306 cytometer.

307

308 For experiments involving lipopolysaccharide (LPS) induced cellular activation, RAW cells were
309 treated with 1 µg/ml of LPS (Merck) for 12-18 hours prior to particle addition. Inhibition of the
310 TLR-4 pathway was achieved by treating cells with 2 µM TAK-242 (Merck) for 6 hours before
311 adding particles. For studies involving cell sorting, RAW cells were seeded in a T-25 flask,
312 incubated with fluorescent PS particles for 2 hours and sorted using BD FACSAria™ Fusion
313 (Becton Dickinson, USA) equipped with a 488 laser, under a two-way purity sort setting. Post
314 sorting, particle-positive and particle-negative cells were separately cultured in 24-well tissue
315 culture plates and allowed to adhere for 2 hours, after which a sequential phagocytosis
316 experiment was performed as described above for RAW cells.

317

318 **Flow cytometry**

319 Experiments involving flow cytometry were performed on BD FACSCelesta™ (Becton
320 Dickinson) and analyzed using FlowJo (Tree Star, Ashland, OR, USA).

321

322 ***Ex vivo* sequential phagocytosis**

323 Studies involving human blood were approved by the Institutional Human Ethics Committee at
324 the Indian Institute of Science (IISc) (approval number 5-15032017). For the *ex vivo* sequential
325 phagocytosis experiment, venous blood was collected in EDTA coated tubes, from healthy
326 volunteers, after obtaining informed consent. PBMCs were isolated using histopaque (Sigma
327 Aldrich, USA) density gradient centrifugation. In brief, 5 ml of whole blood was carefully laid over
328 7.5 ml of histopaque and centrifuged at 500 rcf for 20 min (with the brake turned off) at room
329 temperature. The PBMC layer was collected, and cells were counted, seeded and allowed to
330 adhere in 24-well cell culture plate for one hour at 37°C under 5% CO₂. The bottom-most layer
331 of the density gradient, containing neutrophils and RBCs, was collected separately, and RBCs
332 were lysed using Ammonium-Chloride-Potassium (ACK) lysis buffer (10 ml lysis buffer per 1 ml
333 blood for 8 min at room temperature). The lysis reaction was quenched with 10 volumes of 1 X
334 PBS. The tube was further centrifuged at 400 rcf for 5 min, the supernatant discarded, and the
335 neutrophil enriched pellet resuspended in DMEM cell culture media. Neutrophils and PBMCs
336 were counted and seeded in 24-well plates at a density of 1×10^5 cells per well. Sequential
337 phagocytosis experiments were performed as carried out for RAW cells.

338

339 **Sequential uptake studies in *Drosophila* hemocytes**

340 Transgenic *hmlΔGal4, UAS-GFP Drosophila* stocks (Bloomington stock number 30142) were
341 maintained at 25°C on a 12 h light/ 12 h dark-cycle in a medium comprising 8% cornmeal, 4%
342 sucrose, 2% dextrose, 1.5% yeast extract, 0.8% agar supplemented with 0.4% propionic acid,
343 0.06% orthophosphoric acid and 0.07% benzoic acid. Twenty 3rd instar larvae were dissected,
344 allowed to bleed into buffer consisting of Ringer's solution and 1 mM phenylthiourea (PTU) for
345 30 seconds, and passed through a 100 μm mesh to collect single-cell suspension. Sequential
346 uptake experiments were performed on these cells by incubating them with 3 μm BSA-TRITC
347 adsorbed PS particles (cell to particle ratio of 1:20) for 2 hours at room temperature, removing
348 non-phagocytosed particles by centrifugation followed by the addition of 500 nm-carboxylated
349 PS particles (cell to particle ratio of 1:200) for 2 hours. Finally, the cells were washed, and
350 hemocytes (identified based on GFP expression) were analyzed on a flow cytometer for particle
351 uptake.

352

353 ***In vivo* sequential phagocytosis**

354 All animal studies were conducted in accordance with the Control and Supervision Rules, 1998
355 of the Ministry of Environment and Forest Act (Government of India), and the Institutional
356 Animal Ethics Committee, IISc. Experiments were approved by the Committee for Purpose and
357 Control and Supervision of Experiments on Animals (permit numbers CAF/ethics/546/2017 and
358 CAF/ethics/718/2019). Animals were procured from either IISc's breeding facility (BALB/c mice)
359 or from Hylasco Bio-Technology Pvt Ltd. (a Charles River Laboratories Subsidiary, for C57BL/6
360 mice). BALB/c or C57BL/6 mice (8–14-week-old) were injected intraperitoneally with 6×10^6 500
361 nm-carboxylated fluorescent PS particles. After 2 hours, mice were injected via the
362 intraperitoneal route with 500 nm-carboxylated PS particles labelled with a different fluorophore.
363 Mice were euthanized after 2 hours, and peritoneal exudate was collected by performing
364 peritoneal lavage and cells stained with Ly6G (clone 1A8) and F4/80 (T45-2342) (BD
365 Biosciences) for 20 min at 4 °C. Finally, the cells were stained with PI before being run on the
366 flow cytometer to determine bystander and sequential uptake.

367

368 **Reactive Oxygen Species (ROS) assay**

369 ROS produced by immune cells after phagocytosis of PS particles was assessed using an
370 intracellular probe, Dihydrorhodamine (DHR) 123 (Merck). After the incubation of cells with
371 particles for 2 and 18 hours, media was removed, and cells were incubated in fresh media
372 containing 5 μ M of DHR for 15 min at 37°C. Following this, the probe was quenched with
373 excess 1 X PBS, cells washed and scraped, stained with PI, and median fluorescence intensity
374 of cells determined using a flow cytometer. For positive control for ROS production, RAW cells
375 were stimulated with LPS (1 μ g/ml) for 12-18 hours.

376

377 **Nitric Oxide (NO) assay**

378 For extracellular NO measurement, RAW cells were seeded at a density of 1×10^5 cells per well
379 in a 24-well plate and incubated with PS particles for 36 hours. To determine extracellular NO
380 production, 50 μ l aliquot of cell culture supernatant was mixed with 150 μ l of Griess reagent in a
381 96-well plate. The amount of NO_2^- was determined from a standard curve of Sodium Nitrite. As a
382 positive control for NO production, cells were stimulated with a combination of LPS (100 ng/ml)
383 and IFN γ (100U/ml) (PeproTech, Israel) for 36-hours.

384

385 For intracellular NO measurement, RAW cells were seeded at a density of 1×10^5 cells per well
386 in a 24-well plate. Cells were incubated with PS particles for 36 hours, following which, media
387 was removed and, cells were incubated with 5 μ M 4,5-diaminofluorescein (DAF-2A, Sigma-
388 Aldrich, USA) for 15 min at 37 °C in dark. The fluorescent probe was quenched with 1 X PBS,
389 cells were scraped, stained with PI, and fluorescence intensity (corresponding to the amount of
390 NO present), was measured on a flow cytometer using excitation and an emission wavelength
391 of 488 and 520 nm, respectively.

392

393 **Real-time quantitative PCR (RT-qPCR) Assays**

394 RAW cells, 4×10^5 per well, were seeded in a 24-well plate and allowed to adhere for 2 hours.
395 Cells were treated with 500 nm-carboxylated PS particles or LPS (1 μ g/ml) for 18 hours in
396 triplicates. After incubation, cells were lysed with 1 ml of TRIzol reagent (ThermoFisher
397 Scientific) and total RNA extracted from cells using RNeasy Mini Kits (Qiagen, USA) and
398 reverse transcribed to complementary DNA (cDNA) using iSCRIPT cDNA synthesis kit (Bio-
399 Rad, USA) as per the manufacturer's protocol. The cDNA was analyzed for gene expression
400 using TB Green *Premix Ex Taq I* (Takara Bio Inc., Japan). The RNA expression levels were
401 normalized to the levels of the house-keeping gene, glyceraldehyde 3-phosphate
402 dehydrogenase (*Gapdh*). Sequences of primers used for amplification of human genes are
403 shown in Supplementary Table1.

404

405 **Membrane fluidity measurements using Laurdan**

406 RAW cells, 75×10^3 per well, were seeded in a 96-well black flat-bottom polystyrene plate and
407 allowed to adhere overnight. Cells were incubated with 500 nm-carboxylated PS particles at a
408 cell to particle ratio of 1:50 or 1:200 for 2 hours. As a positive control, cells were treated with 66
409 μ M Methyl- β -cyclodextrin (M β CD) (Merck, USA) for 1 hour. After incubation, media was
410 removed, wells washed with 1 X PBS and incubated with 50 μ L of incomplete media containing
411 5 μ M Laurdan (Avanti® Polar Lipids, Merck, USA) for 30 min at 37°C. Fluorescence was
412 measured with a microplate reader (Tecan, Switzerland). Emission intensity was acquired at
413 440 and 490 nm (excitation=385 nm, 5 nm bandpass) at 37 °C. Generalized
414 polarization⁵⁰(GP_{laurdan}) was calculated from the emission intensities using the following
415 equation:

$$416 \quad GP_{\text{laurdan}} = \frac{I_{440} - I_{490}}{I_{440} + I_{490}}$$

417 I_{440} and I_{490} represent the fluorescence intensity emitted at 440 nm and 490 nm, respectively.

418

419 **Analysis of cellular stiffness using atomic force microscopy (AFM)**

420 RAW cells were seeded at a density of 2×10^5 cells per ml in a 35-mm cell culture dish and
421 allowed to adhere overnight. Particles were added to cells at a ratio of 1:200 for 2 hours to
422 ensure uptake by >95 % cells. Extracellular particles were removed by washing twice with 1 X
423 PBS and cells maintained in DMEM with 10% FBS for AFM measurements. The apparent
424 modulus of elasticity of the cells was measured using an Atomic Force Microscope (XE Bio from
425 Park Systems, Suwon, South Korea) using a V-shaped cantilever (stiffness 0.041 N/m as
426 measured using thermal tuning) with a spherical bead of diameter 5.2 μm made of silicon
427 dioxide (AppNano HYDRA6V-200NG-TL; AppNano, Mountain View, CA). One force-
428 displacement (F-d) curve was obtained per cell for a total of approximately 20 cells in each of
429 the three independent experiments. The force curve corresponding to the approach of the tip
430 towards the substrate was measured, and a constant indentation depth of 200 nm was
431 maintained. Each of these F-d curves was analyzed to obtain the apparent modulus of elasticity
432 of the cell using the Hertzian contact model.⁵¹

433

434 ***In vitro* Bactericidal assays**

435 RAW cells were seeded at a density of 1×10^5 cells per well in a 48-well plate and incubated
436 with 500 nm-carboxylated PS particles, in triplicates, for 18 hours. The cell to particle ratio was
437 1:50, which was optimized (by testing multiple cells to particle ratios – data not shown) to obtain
438 more than 90% for cells with particles. Simultaneously, *E. coli* K12 MG1655 or *Salmonella*
439 *enterica* serovar Typhimurium (*S. Typhimurium*) cultures were grown in Luria-Bertani (LB)
440 media at 37 °C till the late log phase (10 hours). The bacterial load was confirmed by plating the
441 cultures on LB-agar plates and enumerating the colony-forming units (CFU). Antibiotic-free
442 DMEM cell culture media was used for further steps in the experiment. After incubating cells
443 with particles, the wells were washed with 1 X PBS to remove non-phagocytosed particles.
444 Bacteria were then added to the cells at the desired multiplicity of infection (MOI), and the plate
445 was centrifuged at 400 rcf for 5 min to allow the bacteria to settle. The plate was incubated at
446 37°C under 5% CO₂ for one hour to allow phagocytosis of bacteria by RAW cells. After this,
447 media was removed, wells washed with 1 X PBS, and cells were further incubated in media
448 containing 100 $\mu\text{g/ml}$ gentamicin (HiMedia Laboratories, India) for one hour to kill extracellular
449 bacteria. The viable bacteria inside RAW cells at different time points post-infection were
450 enumerated by lysing the cells with 0.1% Triton X-100 for 10 min and plating the cell lysates on
451 LB-Agar plates to determine bacterial CFU. For all time points beyond 2 hours post-infection,

452 wells were washed with 1 X PBS and cells were maintained in media containing 25 µg/ml of
453 gentamicin.

454

455

456 ***In vivo* killing assays-*E. coli***

457 C57BL/6 mice (weighing 20 – 30 grams, 8-14-week-old) were injected intraperitoneally 1×10^{10}
458 500 nm-carboxylated PS particles. Control mice were injected with saline. After 2 hours, mice
459 were injected intraperitoneally with $\sim 5 \times 10^7$ *E. coli*. Next, 2- or 6- hours of bacterial injection,
460 mice were euthanized, peritoneal lavage performed with 5 ml of ice-cold PBS-EDTA, and
461 peritoneal exudates collected. The peritoneal exudate cells were stained for live dead using
462 Zombie Aqua Fixable Viability dye (BD Biosciences), fixed with 1.6% paraformaldehyde (PFA),
463 and finally stained with the following antibodies for 20 min at 4 °C: Ly6G (1A8), Ly6C (AL-21),
464 CD11b (M1/70) and F4/80 (T45-2342) and analyzed on a flow cytometer. Further, mice were
465 dissected after peritoneal lavage to collect spleen, kidney, and liver. The organs were
466 mechanically homogenized in 1 X PBS containing 0.1 % Triton X-100 using a pestle. Serial
467 dilutions of each lysate were plated on LB agar plates and incubated overnight at 37 °C. CFU
468 obtained were enumerated to determine the bacterial load for each organ.

469

470 ***In vivo* killing assays-*S. epidermidis***

471 *S. epidermidis*: sGFP expressing plasmid (pTH100-Addgene plasmid #84458)⁵² was
472 transformed into *E. coli* DC10B cells.⁵³ Plasmids extracted from DC10B cells were
473 electroporated into *S. epidermidis* (ATCC122293) strain. The cells were plated onto Tryptic soya
474 agar (TSA) plates containing 10 µg/ml chloramphenicol and incubated at 30°C for 24 hours.
475 Fluorescent green colonies were picked for further experiments.

476

477 C57BL/6 mice (weighing 20 – 30 grams, 8-14-week-old) were injected intraperitoneally with $1 \times$
478 10^9 500 nm-carboxylated PS particles. Control mice were injected with saline. After 2 hours,
479 mice were injected intraperitoneally with $\sim 3 \times 10^8$ *S. epidermidis*. After 3- or 24 hours of *S.*
480 *epidermidis* injection, mice were euthanized, peritoneal lavage performed with 5 ml of ice-cold
481 PBS-EDTA, and peritoneal exudates collected. The peritoneal exudate cells were stained for
482 live dead using Zombie Aqua Fixable Viability dye (BD Biosciences (USA), fixed with 1.6% PFA,
483 and finally stained with the following antibodies for 20 min at 4 °C: CD11b (M1/70), F4/80 (T45-
484 2342) Ly6G (1A8), Ly6C (AL-21), and analyzed on a flow cytometer. Further, mice were
485 dissected after peritoneal lavage to collect spleen, kidney, and liver. The organs were

486 mechanically homogenized in 1 X PBS containing 0.1 % TritonX-100 using a pestle. Serial
487 dilutions of each lysate were plated on Tryptic Soya agar plates and incubated overnight at 37
488 °C. CFU obtained were enumerated to determine the bacterial load for each organ.

489

490 **Expression of activation markers on peritoneal macrophages**

491 C57BL/6 mice were euthanized, and peritoneal lavage was performed with 5 ml of ice-cold
492 PBS-EDTA. Peritoneal exudates were centrifuged at 400 rcf for 5 min, and the cell pellet was
493 resuspended in DMEM complete media. Cells were counted using a hemocytometer. 5×10^5
494 cells were seeded in each well of a 6-well plate and incubated at 37°C for 2 hours to allow
495 peritoneal macrophages to adhere. Non-adhered cells were removed by washing the wells
496 thrice with 1 X PBS. Fluorescent-labeled 500 nm-carboxylated PS particles were added to cells
497 at a ratio of 1:100 (low) or 1:1000 (high) and incubated for 2 hours. Cells were washed with ice
498 cold PBS-EDTA (three times), scraped and collected in FACS tubes, and stained using Zombie
499 Aqua Fixable Viability dye. Finally, cells were stained with a combination of the following
500 antibodies for 30 mins at 4°C: CD11b (M1/70), CD38 (90), CD54 (3E2), CD62L (MEL-14), CD86
501 (GL-1), F4/80 (T45-2342) and Ly6C (AL-21) (BD Biosciences). The expression of activation
502 markers was determined using a flow cytometer.

503

504 **Statistics**

505 At least three independent experiments were performed (unless explicitly stated differently), and
506 data from biological duplicates of a single independent experiment are reported through a single
507 mean value. For data involving comparisons between 2 groups, Student's *t*-test or Mann-
508 Whitney test or Welch's *t*-test were used. For data involving comparisons between multiple
509 groups, one-way ANOVA followed by the Bonferroni *post-hoc* test was used for statistical
510 comparisons.

511

512 **Acknowledgements:** We thank Monisha for assistance with the atomic force microscope. We
513 acknowledge the support of the staff at the central animal facility and flow cytometry facility,
514 IISc. This work was supported by the DBT/Wellcome Trust India Alliance Fellowship [grant
515 number IA/I/19/1/504265] awarded to SJ. This work was partly supported by a Science and
516 Engineering Board, Department of Science and Technology, Govt. of India [grant number
517 ECR/2016/000629] to SJ. This work was also partly supported by the R. I. Mazumdar young
518 investigator fellowship at the Indian Institute of Science. PS is supported by a research
519 fellowship from University Grants Commission, Govt. of India.

520

521 **References:**

522

- 523 (1) Mosser, D. M.; Hamidzadeh, K.; Goncalves, R. Macrophages and the Maintenance of
524 Homeostasis. *Cellular & Molecular Immunology* **2021**, *18* (3), 579–587.
525 <https://doi.org/10.1038/s41423-020-00541-3>.
- 526 (2) Nicolás-Ávila, J. Á.; Adrover, J. M.; Hidalgo, A. Neutrophils in Homeostasis, Immunity, and Cancer.
527 *Immunity* **2017**, *46* (1), 15–28. <https://doi.org/10.1016/j.immuni.2016.12.012>.
- 528 (3) Gordon, S. Phagocytosis: An Immunobiologic Process. *Immunity* **2016**, *44* (3), 463–475.
529 <https://doi.org/10.1016/j.immuni.2016.02.026>.
- 530 (4) Gustafson, H. H.; Holt-Casper, D.; Grainger, D. W.; Ghandehari, H. Nanoparticle Uptake: The
531 Phagocyte Problem. *Nano Today* **2015**, *10* (4), 487–510.
532 <https://doi.org/10.1016/j.nantod.2015.06.006>.
- 533 (5) Hu, M.; Palić, D. Micro- and Nano-Plastics Activation of Oxidative and Inflammatory Adverse
534 Outcome Pathways. *Redox Biology* **2020**, *37*, 101620.
535 <https://doi.org/10.1016/j.redox.2020.101620>.
- 536 (6) Kaufmann, S. H. E.; Dorhoi, A. Molecular Determinants in Phagocyte-Bacteria Interactions.
537 *Immunity* **2016**, *44* (3), 476–491. <https://doi.org/10.1016/j.immuni.2016.02.014>.
- 538 (7) Zanganeh, S.; Hutter, G.; Spitler, R.; Lenkov, O.; Mahmoudi, M.; Shaw, A.; Pajarinen, J. S.;
539 Nejadnik, H.; Goodman, S.; Moseley, M.; Coussens, L. M.; Daldrup-Link, H. E. Iron Oxide
540 Nanoparticles Inhibit Tumour Growth by Inducing Pro-Inflammatory Macrophage Polarization in
541 Tumour Tissues. *Nat Nanotechnol* **2016**, *11* (11), 986–994.
542 <https://doi.org/10.1038/nnano.2016.168>.
- 543 (8) Miao, X.; Leng, X.; Zhang, Q. The Current State of Nanoparticle-Induced Macrophage Polarization
544 and Reprogramming Research. *Int J Mol Sci* **2017**, *18* (2). <https://doi.org/10.3390/ijms18020336>.
- 545 (9) Laskar, A.; Eilertsen, J.; Li, W.; Yuan, X.-M. SPION Primes THP1 Derived M2 Macrophages towards
546 M1-like Macrophages. *Biochemical and Biophysical Research Communications* **2013**, *441* (4),
547 737–742. <https://doi.org/10.1016/j.bbrc.2013.10.115>.
- 548 (10) Casey, L. M.; Kakade, S.; Decker, J. T.; Rose, J. A.; Deans, K.; Shea, L. D.; Pearson, R. M. Cargo-Less
549 Nanoparticles Program Innate Immune Cell Responses to Toll-like Receptor Activation.
550 *Biomaterials* **2019**, *218*, 119333. <https://doi.org/10.1016/j.biomaterials.2019.119333>.
- 551 (11) Fuchs, A.-K.; Syrovets, T.; Haas, K. A.; Loos, C.; Musyanovych, A.; Mailänder, V.; Landfester, K.;
552 Simmet, T. Carboxyl- and Amino-Functionalized Polystyrene Nanoparticles Differentially Affect
553 the Polarization Profile of M1 and M2 Macrophage Subsets. *Biomaterials* **2016**, *85*, 78–87.
554 <https://doi.org/10.1016/j.biomaterials.2016.01.064>.
- 555 (12) Huang, Y.-J.; Hung, K.-C.; Hung, H.-S.; Hsu, S. Modulation of Macrophage Phenotype by
556 Biodegradable Polyurethane Nanoparticles: Possible Relation between Macrophage Polarization
557 and Immune Response of Nanoparticles. *ACS Appl. Mater. Interfaces* **2018**, *10* (23), 19436–19448.
558 <https://doi.org/10.1021/acsami.8b04718>.
- 559 (13) Garcia, G.; Kim, M.-H.; Morikis, V. A.; Simon, S. I. Neutrophil Inflammatory Response Is
560 Downregulated by Uptake of Superparamagnetic Iron Oxide Nanoparticle Therapeutics. *Front.*
561 *Immunol.* **2020**, *11*. <https://doi.org/10.3389/fimmu.2020.571489>.
- 562 (14) Hwang, J.; Choi, D.; Han, S.; Jung, S. Y.; Choi, J.; Hong, J. Potential Toxicity of Polystyrene
563 Microplastic Particles. *Scientific Reports* **2020**, *10* (1), 7391. <https://doi.org/10.1038/s41598-020-64464-9>.
- 564 (15) Kusaka, T.; Nakayama, M.; Nakamura, K.; Ishimiya, M.; Furusawa, E.; Ogasawara, K. Effect of Silica
565 Particle Size on Macrophage Inflammatory Responses. *PLOS ONE* **2014**, *9* (3), e92634.
566 <https://doi.org/10.1371/journal.pone.0092634>.
- 567

- 568 (16) Chou, C.-C.; Chen, W.; Hung, Y.; Mou, C.-Y. Molecular Elucidation of Biological Response to
569 Mesoporous Silica Nanoparticles In Vitro and In Vivo. *ACS Appl. Mater. Interfaces* **2017**, *9* (27),
570 22235–22251. <https://doi.org/10.1021/acsami.7b05359>.
- 571 (17) Jayaram, D. T.; Kumar, A.; Kippner, L. E.; Ho, P.-Y.; Kemp, M. L.; Fan, Y.; Payne, C. K. TiO₂
572 Nanoparticles Generate Superoxide and Alter Gene Expression in Human Lung Cells. *RSC Adv.*
573 **2019**, *9* (43), 25039–25047. <https://doi.org/10.1039/C9RA04037D>.
- 574 (18) Wang, M.; Li, J.; Dong, S.; Cai, X.; Simaiti, A.; Yang, X.; Zhu, X.; Luo, J.; Jiang, L.-H.; Du, B.; Yu, P.;
575 Yang, W. Silica Nanoparticles Induce Lung Inflammation in Mice via ROS/PARP/TRPM2 Signaling-
576 Mediated Lysosome Impairment and Autophagy Dysfunction. *Particle and Fibre Toxicology* **2020**,
577 *17* (1), 23. <https://doi.org/10.1186/s12989-020-00353-3>.
- 578 (19) Attarilar, S.; Yang, J.; Ebrahimi, M.; Wang, Q.; Liu, J.; Tang, Y.; Yang, J. The Toxicity Phenomenon
579 and the Related Occurrence in Metal and Metal Oxide Nanoparticles: A Brief Review From the
580 Biomedical Perspective. *Front. Bioeng. Biotechnol.* **2020**, *8*.
581 <https://doi.org/10.3389/fbioe.2020.00822>.
- 582 (20) Gaharwar, U. S.; Kumar, S.; Rajamani, P. Iron Oxide Nanoparticle-Induced Hematopoietic and
583 Immunological Response in Rats. *RSC Adv.* **2020**, *10* (59), 35753–35764.
584 <https://doi.org/10.1039/D0RA05901C>.
- 585 (21) Liu, Y.; Hardie, J.; Zhang, X.; Rotello, V. M. Effects of Engineered Nanoparticles on the Innate
586 Immune System. *Seminars in Immunology* **2017**, *34*, 25–32.
587 <https://doi.org/10.1016/j.smim.2017.09.011>.
- 588 (22) Islam, M. A.; Pröll, M.; Hölker, M.; Tholen, E.; Tesfaye, D.; Looft, C.; Schellander, K.; Cinar, M. U.
589 Alveolar Macrophage Phagocytic Activity Is Enhanced with LPS Priming, and Combined
590 Stimulation of LPS and Lipoteichoic Acid Synergistically Induce pro-Inflammatory Cytokines in
591 Pigs. *Innate Immun* **2013**, *19* (6), 631–643. <https://doi.org/10.1177/1753425913477166>.
- 592 (23) Matsunaga, N.; Tsuchimori, N.; Matsumoto, T.; Ii, M. TAK-242 (Resatorvid), a Small-Molecule
593 Inhibitor of Toll-like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with
594 Interactions between TLR4 and Its Adaptor Molecules. *Mol Pharmacol* **2011**, *79* (1), 34–41.
595 <https://doi.org/10.1124/mol.110.068064>.
- 596 (24) Andreakos, E.; Sacre, S. M.; Smith, C.; Lundberg, A.; Kiriakidis, S.; Stonehouse, T.; Monaco, C.;
597 Feldmann, M.; Foxwell, B. M. Distinct Pathways of LPS-Induced NF-κB Activation and Cytokine
598 Production in Human Myeloid and Nonmyeloid Cells Defined by Selective Utilization of MyD88
599 and Mal/TIRAP. *Blood* **2004**, *103* (6), 2229–2237. <https://doi.org/10.1182/blood-2003-04-1356>.
- 600 (25) Hellebrekers, P.; Hietbrink, F.; Vrisekoop, N.; Leenen, L. P. H.; Koenderman, L. Neutrophil
601 Functional Heterogeneity: Identification of Competitive Phagocytosis. *Front. Immunol.* **2017**, *8*.
602 <https://doi.org/10.3389/fimmu.2017.01498>.
- 603 (26) Sachdeva, K.; Goel, M.; Sundaramurthy, V. Heterogeneity in the Endocytic Capacity of Individual
604 Macrophage in a Population Determines Its Subsequent Phagocytosis, Infectivity and Subcellular
605 Trafficking. *Traffic* **2020**, *21* (8), 522–533. <https://doi.org/10.1111/tra.12752>.
- 606 (27) Schumann, J. It Is All about Fluidity: Fatty Acids and Macrophage Phagocytosis. *European Journal*
607 *of Pharmacology* **2016**, *785*, 18–23. <https://doi.org/10.1016/j.ejphar.2015.04.057>.
- 608 (28) Erwig, L. P.; Gow, N. A. R. Interactions of Fungal Pathogens with Phagocytes. *Nature Reviews*
609 *Microbiology* **2016**, *14* (3), 163–176. <https://doi.org/10.1038/nrmicro.2015.21>.
- 610 (29) Spaan, A. N.; Surewaard, B. G. J.; Nijland, R.; van Strijp, J. A. G. Neutrophils Versus Staphylococcus
611 Aureus: A Biological Tug of War. *Annual Review of Microbiology* **2013**, *67* (1), 629–650.
612 <https://doi.org/10.1146/annurev-micro-092412-155746>.
- 613 (30) Wilhelm, S.; Tavares, A. J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H. F.; Chan, W. C. W. Analysis of
614 Nanoparticle Delivery to Tumours. *Nature Reviews Materials* **2016**, *1* (5), 16014.
615 <https://doi.org/10.1038/natrevmats.2016.14>.

- 616 (31) Gad, S. C.; Sharp, K. L.; Montgomery, C.; Payne, J. D.; Goodrich, G. P. Evaluation of the Toxicity of
617 Intravenous Delivery of Auroshell Particles (Gold–Silica Nanoshells). *Int J Toxicol* **2012**, *31* (6),
618 584–594. <https://doi.org/10.1177/1091581812465969>.
- 619 (32) Cho, M.; Cho, W.-S.; Choi, M.; Kim, S. J.; Han, B. S.; Kim, S. H.; Kim, H. O.; Sheen, Y. Y.; Jeong, J.
620 The Impact of Size on Tissue Distribution and Elimination by Single Intravenous Injection of Silica
621 Nanoparticles. *Toxicology Letters* **2009**, *189* (3), 177–183.
622 <https://doi.org/10.1016/j.toxlet.2009.04.017>.
- 623 (33) Hadipour Moghaddam, S. P.; Mohammadpour, R.; Ghandehari, H. In Vitro and in Vivo Evaluation
624 of Degradation, Toxicity, Biodistribution, and Clearance of Silica Nanoparticles as a Function of
625 Size, Porosity, Density, and Composition. *Journal of Controlled Release* **2019**, *311–312*, 1–15.
626 <https://doi.org/10.1016/j.jconrel.2019.08.028>.
- 627 (34) Su, C.; Liu, Y.; Li, R.; Wu, W.; Fawcett, J. P.; Gu, J. Absorption, Distribution, Metabolism and
628 Excretion of the Biomaterials Used in Nanocarrier Drug Delivery Systems. *Advanced Drug Delivery*
629 *Reviews* **2019**, *143*, 97–114. <https://doi.org/10.1016/j.addr.2019.06.008>.
- 630 (35) Zhang, A.; Meng, K.; Liu, Y.; Pan, Y.; Qu, W.; Chen, D.; Xie, S. Absorption, Distribution,
631 Metabolism, and Excretion of Nanocarriers in Vivo and Their Influences. *Advances in Colloid and*
632 *Interface Science* **2020**, *284*, 102261. <https://doi.org/10.1016/j.cis.2020.102261>.
- 633 (36) Bourquin, J.; Milosevic, A.; Hauser, D.; Lehner, R.; Blank, F.; Petri-Fink, A.; Rothen-Rutishauser, B.
634 Biodistribution, Clearance, and Long-Term Fate of Clinically Relevant Nanomaterials. *Advanced*
635 *Materials* **2018**, *30* (19), 1704307. <https://doi.org/10.1002/adma.201704307>.
- 636 (37) Martinez, F. O.; Gordon, S. The M1 and M2 Paradigm of Macrophage Activation: Time for
637 Reassessment. *F1000Prime Rep* **2014**, *6*. <https://doi.org/10.12703/P6-13>.
- 638 (38) Orecchioni, M.; Ghosheh, Y.; Pramod, A. B.; Ley, K. Macrophage Polarization: Different Gene
639 Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages.
640 *Front. Immunol.* **2019**, *10*. <https://doi.org/10.3389/fimmu.2019.01084>.
- 641 (39) Rayees, S.; Rochford, I.; Joshi, J. C.; Joshi, B.; Banerjee, S.; Mehta, D. Macrophage TLR4 and PAR2
642 Signaling: Role in Regulating Vascular Inflammatory Injury and Repair. *Front. Immunol.* **2020**, *11*.
643 <https://doi.org/10.3389/fimmu.2020.02091>.
- 644 (40) A-Gonzalez, N.; Quintana, J. A.; García-Silva, S.; Mazariegos, M.; González de la Aleja, A.; Nicolás-
645 Ávila, J. A.; Walter, W.; Adrover, J. M.; Crainiciuc, G.; Kuchroo, V. K.; Rothlin, C. V.; Peinado, H.;
646 Castrillo, A.; Ricote, M.; Hidalgo, A. Phagocytosis Imprints Heterogeneity in Tissue-Resident
647 Macrophages. *J Exp Med* **2017**, *214* (5), 1281–1296. <https://doi.org/10.1084/jem.20161375>.
- 648 (41) Casey, L. M.; Kakade, S.; Decker, J. T.; Rose, J. A.; Deans, K.; Shea, L. D.; Pearson, R. M. Cargo-Less
649 Nanoparticles Program Innate Immune Cell Responses to Toll-like Receptor Activation.
650 *Biomaterials* **2019**, *218*, 119333. <https://doi.org/10.1016/j.biomaterials.2019.119333>.
- 651 (42) Fromen, C. A.; Kelley, W. J.; Fish, M. B.; Adili, R.; Noble, J.; Hoenerhoff, M. J.; Holinstat, M.; Eniola-
652 Adefeso, O. Neutrophil–Particle Interactions in Blood Circulation Drive Particle Clearance and
653 Alter Neutrophil Responses in Acute Inflammation. *ACS Nano* **2017**, *11* (11), 10797–10807.
654 <https://doi.org/10.1021/acsnano.7b03190>.
- 655 (43) Getts, D. R.; Terry, R. L.; Getts, M. T.; Deffrasnes, C.; Müller, M.; van Vreden, C.; Ashhurst, T. M.;
656 Chami, B.; McCarthy, D.; Wu, H.; Ma, J.; Martin, A.; Shae, L. D.; Witting, P.; Kansas, G. S.; Kühn, J.;
657 Hafezi, W.; Campbell, I. L.; Reilly, D.; Say, J.; Brown, L.; White, M. Y.; Cordwell, S. J.; Chadban, S. J.;
658 Thorp, E. B.; Bao, S.; Miller, S. D.; King, N. J. C. Therapeutic Inflammatory Monocyte Modulation
659 Using Immune-Modifying Microparticles. *Sci Transl Med* **2014**, *6* (219), 219ra7.
660 <https://doi.org/10.1126/scitranslmed.3007563>.
- 661 (44) Saito, E.; Kuo, R.; Pearson, R. M.; Gohel, N.; Cheung, B.; King, N. J. C.; Miller, S. D.; Shea, L. D.
662 Designing Drug-Free Biodegradable Nanoparticles to Modulate Inflammatory Monocytes and

- 663 Neutrophils for Ameliorating Inflammation. *Journal of Controlled Release* **2019**, *300*, 185–196.
664 <https://doi.org/10.1016/j.jconrel.2019.02.025>.
- 665 (45) Berenson, C. S.; Garlipp, M. A.; Grove, L. J.; Maloney, J.; Sethi, S. Impaired Phagocytosis of
666 Nontypeable Haemophilus Influenzae by Human Alveolar Macrophages in Chronic Obstructive
667 Pulmonary Disease. *The Journal of Infectious Diseases* **2006**, *194* (10), 1375–1384.
668 <https://doi.org/10.1086/508428>.
- 669 (46) Fitzpatrick, A. M.; Holguin, F.; Teague, W. G.; Brown, L. A. S. Alveolar Macrophage Phagocytosis Is
670 Impaired in Children with Poorly Controlled Asthma. *Journal of Allergy and Clinical Immunology*
671 **2008**, *121* (6), 1372–1378.e3. <https://doi.org/10.1016/j.jaci.2008.03.008>.
- 672 (47) Schrijvers, D. M.; De Meyer, G. R. Y.; Kockx, M. M.; Herman, A. G.; Martinet, W. Phagocytosis of
673 Apoptotic Cells by Macrophages Is Impaired in Atherosclerosis. *Arteriosclerosis, Thrombosis, and*
674 *Vascular Biology* **2005**, *25* (6), 1256–1261.
675 <https://doi.org/10.1161/01.ATV.0000166517.18801.a7>.
- 676 (48) Szondy, Z.; Garabuczi, É.; Joós, G.; Tsay, G. J.; Sarang, Z. Impaired Clearance of Apoptotic Cells in
677 Chronic Inflammatory Diseases: Therapeutic Implications. *Front Immunol* **2014**, *5*.
678 <https://doi.org/10.3389/fimmu.2014.00354>.
- 679 (49) Jhunjhunwala, S.; Balmert, S. C.; Raimondi, G.; Dons, E.; Nichols, E. E.; Thomson, A. W.; Little, S. R.
680 Controlled Release Formulations of IL-2, TGF-β1 and Rapamycin for the Induction of Regulatory T
681 Cells. *J Control Release* **2012**, *159* (1), 78–84. <https://doi.org/10.1016/j.jconrel.2012.01.013>.
- 682 (50) Parasassi, T.; De Stasio, G.; Ravagnan, G.; Rusch, R. M.; Gratton, E. Quantitation of Lipid Phases in
683 Phospholipid Vesicles by the Generalized Polarization of Laurdan Fluorescence. *Biophys J* **1991**,
684 *60* (1), 179–189.
- 685 (51) Balakrishnan, S.; Mathad, S. S.; Sharma, G.; Raju, S. R.; Reddy, U. B.; Das, S.; Ananthasuresh, G. K.
686 A Nondimensional Model Reveals Alterations in Nuclear Mechanics upon Hepatitis C Virus
687 Replication. *Biophysical Journal* **2019**, *116* (7), 1328–1339.
688 <https://doi.org/10.1016/j.bpj.2019.02.013>.
- 689 (52) de Jong, N. W. M.; van der Horst, T.; van Strijp, J. A. G.; Nijland, R. Fluorescent Reporters for
690 Markerless Genomic Integration in Staphylococcus Aureus. *Sci Rep* **2017**, *7*, 43889.
691 <https://doi.org/10.1038/srep43889>.
- 692 (53) Monk, I. R.; Shah, I. M.; Xu, M.; Tan, M.-W.; Foster, T. J. Transforming the Untransformable:
693 Application of Direct Transformation To Manipulate Genetically Staphylococcus Aureus and
694 Staphylococcus Epidermidis. *mBio* **3** (2), e00277-11. <https://doi.org/10.1128/mBio.00277-11>.
695